Online Information About Side Effects and Safety Concerns of Semaglutide: Mixed Methods Study of YouTube Videos.
JMIR Infodemiology · 2025
Last updated 2026-05-28A study analyzed 96 full-length YouTube videos and 93 short videos about semaglutide (including brand names Ozempic, Wegovy, and Rybelsus). Full-length videos had higher content quality than short videos, and those from health sources were even better. However, most videos missed key topics like long-term effects, lasting side effects, and risks of fake drugs, and the tone was mostly neutral.
AI summary of the abstract below.
| Journal | JMIR Infodemiology, 2025 |
|---|---|
| Citations | 3 |
| Molecules | semaglutide |
| Conditions studied | Type 2 Diabetes, Obesity |
Abstract
BACKGROUND: Social media has been extensively used by the public to seek information and share views on health issues. Recently, the proper and off-label use of semaglutide drugs for weight loss has attracted huge media attention and led to temporary supply shortages.
OBJECTIVE: The aim of this study was to perform a content analysis on English YouTube (Google) videos related to semaglutide.
METHODS: YouTube was searched with the words semaglutide, Ozempic, Wegovy, and Rybelsus. The first 30 full-length videos (videos without a time limit) and 30 shorts (videos that are no longer than 1 minute) resulting from each search word were recorded. After discounting duplicates resulting from multiple searches, a total of 96 full-length videos and 93 shorts were analyzed. Video content was evaluated by 3 tools, that is, a custom checklist, a Global Quality Score (GQS), and Modified DISCERN. Readability and sentiment of the transcripts were also assessed.
RESULTS: There was no significant difference in the mean number of views between full-length videos and shorts (mean 288,563.1, SD 513,598.3 vs mean 188,465.2, SD 780,376.2, P=.30). The former had better content quality in terms of GQS, Modified DISCERN, and the number of mentioned points from the custom checklist (all P<.001). The transcript readability of both types of videos was at a fairly easy level and mainly had a neutral tone. Full-length videos from health sources had a higher content quality in terms of GQS and Modified DISCERN (both P<.001) than their counterparts.
CONCLUSIONS: The analyzed videos lacked coverage of several important aspects, including the lack of long-term data, the persistence of side effects due to the long half-life of semaglutide, and the risk of counterfeit drugs. It is crucial for the public to be aware that videos cannot replace consultations with physicians.
Verbatim abstract via PubMed 40198905 ↗
Related research
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
- Once-Weekly Semaglutide in Adults with Overweight or Obesity.
- Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.
- A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
- Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
- Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.
- Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity.